Comparison Overview

Cipla

VS

MACLEODS PHARMACEUTICALS LTD.

Cipla

Lower Parel, Ganpatrao Kadam Marg,, Mumbai, Maharashtra, IN, 400013
Last Update: 2026-01-24
Between 750 and 799

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 50,326
Subsidiaries: 7
12-month incidents
0
Known data breaches
0
Attack type number
0

MACLEODS PHARMACEUTICALS LTD.

304, Atlanta Arcade Marol Church Road, Mumbai, 400059, IN
Last Update: 2026-01-19

A vertically integrated, Global Pharmaceutical Company. Established in 1989, we are engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment. We develop, manufacture, and globally distribute a broad range of pharmaceutical products across therapies in multiple dosage forms such as solid orals, liquid orals, topical formulations, injectables (Dry Powder) metered dose inhalers and dry powder inhalers. Our Vision To be a leading global pharmaceutical company by providing high quality, affordable and innovative therapeutic solutions for patients with diverse medical needs. Our Mission To contribute towards improving patients’ quality of life across the globe, by providing effective and accessible medicines.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 11,821
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/cipla.jpeg
Cipla
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/macleods-pharmaceuticals-ltd..jpeg
MACLEODS PHARMACEUTICALS LTD.
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Cipla
100%
Compliance Rate
0/4 Standards Verified
MACLEODS PHARMACEUTICALS LTD.
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Cipla in 2026.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for MACLEODS PHARMACEUTICALS LTD. in 2026.

Incident History — Cipla (X = Date, Y = Severity)

Cipla cyber incidents detection timeline including parent company and subsidiaries

Incident History — MACLEODS PHARMACEUTICALS LTD. (X = Date, Y = Severity)

MACLEODS PHARMACEUTICALS LTD. cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/cipla.jpeg
Cipla
Incidents

No Incident

https://images.rankiteo.com/companyimages/macleods-pharmaceuticals-ltd..jpeg
MACLEODS PHARMACEUTICALS LTD.
Incidents

No Incident

FAQ

Cipla company demonstrates a stronger AI Cybersecurity Score compared to MACLEODS PHARMACEUTICALS LTD. company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, MACLEODS PHARMACEUTICALS LTD. company has disclosed a higher number of cyber incidents compared to Cipla company.

In the current year, MACLEODS PHARMACEUTICALS LTD. company and Cipla company have not reported any cyber incidents.

Neither MACLEODS PHARMACEUTICALS LTD. company nor Cipla company has reported experiencing a ransomware attack publicly.

Neither MACLEODS PHARMACEUTICALS LTD. company nor Cipla company has reported experiencing a data breach publicly.

Neither MACLEODS PHARMACEUTICALS LTD. company nor Cipla company has reported experiencing targeted cyberattacks publicly.

Neither Cipla company nor MACLEODS PHARMACEUTICALS LTD. company has reported experiencing or disclosing vulnerabilities publicly.

Neither Cipla nor MACLEODS PHARMACEUTICALS LTD. holds any compliance certifications.

Neither company holds any compliance certifications.

Cipla company has more subsidiaries worldwide compared to MACLEODS PHARMACEUTICALS LTD. company.

Cipla company employs more people globally than MACLEODS PHARMACEUTICALS LTD. company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither Cipla nor MACLEODS PHARMACEUTICALS LTD. holds SOC 2 Type 1 certification.

Neither Cipla nor MACLEODS PHARMACEUTICALS LTD. holds SOC 2 Type 2 certification.

Neither Cipla nor MACLEODS PHARMACEUTICALS LTD. holds ISO 27001 certification.

Neither Cipla nor MACLEODS PHARMACEUTICALS LTD. holds PCI DSS certification.

Neither Cipla nor MACLEODS PHARMACEUTICALS LTD. holds HIPAA certification.

Neither Cipla nor MACLEODS PHARMACEUTICALS LTD. holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

Typemill is a flat-file, Markdown-based CMS designed for informational documentation websites. A reflected Cross-Site Scripting (XSS) exists in the login error view template `login.twig` of versions 2.19.1 and below. The `username` value can be echoed back without proper contextual encoding when authentication fails. An attacker can execute script in the login page context. This issue has been fixed in version 2.19.2.

Risk Information
cvss3
Base: 5.4
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:L/I:L/A:N
Description

A DOM-based Cross-Site Scripting (XSS) vulnerability exists in the DomainCheckerApp class within domain/script.js of Sourcecodester Domain Availability Checker v1.0. The vulnerability occurs because the application improperly handles user-supplied data in the createResultElement method by using the unsafe innerHTML property to render domain search results.

Description

A Remote Code Execution (RCE) vulnerability exists in Sourcecodester Modern Image Gallery App v1.0 within the gallery/upload.php component. The application fails to properly validate uploaded file contents. Additionally, the application preserves the user-supplied file extension during the save process. This allows an unauthenticated attacker to upload arbitrary PHP code by spoofing the MIME type as an image, leading to full system compromise.

Description

A UNIX symbolic link following issue in the jailer component in Firecracker version v1.13.1 and earlier and 1.14.0 on Linux may allow a local host user with write access to the pre-created jailer directories to overwrite arbitrary host files via a symlink attack during the initialization copy at jailer startup, if the jailer is executed with root privileges. To mitigate this issue, users should upgrade to version v1.13.2 or 1.14.1 or above.

Risk Information
cvss3
Base: 6.0
Severity: LOW
CVSS:3.1/AV:L/AC:L/PR:H/UI:N/S:U/C:N/I:H/A:H
cvss4
Base: 6.0
Severity: LOW
CVSS:4.0/AV:L/AC:L/AT:N/PR:H/UI:N/VC:N/VI:N/VA:N/SC:N/SI:H/SA:H/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

An information disclosure vulnerability exists in the /srvs/membersrv/getCashiers endpoint of the Aptsys gemscms backend platform thru 2025-05-28. This unauthenticated endpoint returns a list of cashier accounts, including names, email addresses, usernames, and passwords hashed using MD5. As MD5 is a broken cryptographic function, the hashes can be easily reversed using public tools, exposing user credentials in plaintext. This allows remote attackers to perform unauthorized logins and potentially gain access to sensitive POS operations or backend functions.